Plan on retiring but still paying off your mortgage? We want to hear from you
A recent Royal LePage survey, conducted by Léger, shows nearly a third of Canadians retiring within the next two years won't have their home paid off. (iStock / Getty Images Plus)
Are you nearing retirement and still paying off your mortgage? You're not alone.
A new Royal LePage survey, conducted by Leger, reveals a shifting financial reality for Canadians on the cusp of retirement. Nearly three in 10 Canadians (29 per cent) planning to retire in the next two years say they'll still be making mortgage payments when they leave the workforce, with almost half (47 per cent) saying they don't intend to downsize their homes.
Statistics Canada data also shows that the average retirement age in the country has gradually increased, up to 65.3 in 2024 compared to 64.3 in 2020.
Are you approaching retirement with mortgage debt still on the books? Are you planning to stay in your current home, or are you considering a move to a smaller space?
Whether you've made your move, are in the midst of planning, or are trying to figure it all out, we want to hear from you.
Share your story by emailing us at dotcom@bellmedia.ca with your name, general location and phone number in case we want to follow up. Your comments may be used in a CTVNews.ca story.
The online survey of 1,626 Canadians aged 18 and up was conducted between May 2 and May 4, 2025, using Leger's online panel that has approximately 400,000 members nationwide and a 90 per cent retention rate.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
19 minutes ago
- Globe and Mail
Northstar Reports First Quarter 2025 Financial and Operating Results
CALGARY, AB , May 30, 2025 /CNW/ - Northstar Clean Technologies Inc. (TSXV: ROOF) (OTCQB: ROOOF) (" Northstar" or the " Company") is pleased to announce our financial and operating results for the three-month period ended March 31 , 2025. Selected financial and operational information is set out below and should be read in conjunction with the Company's March 31, 2025 Condensed Interim Financial Statements and the related Management's Discussion and Analysis, which are available for review at or the Company's website at First Quarter 2025 Financial and Operational Highlights The first quarter of 2025 witnessed a number of significant developments and achievements, together with a few key funding achievements subsequent to the quarter-end, namely: Operational The Company successfully completed construction efforts of the Empower Calgary Facility; and Following the successful completion of construction, the Company began the important task of commissioning the Empower Calgary Facility. The Company's asphalt shingle reprocessing facilities are broadly broken into two main phases: (1) feedstock preparation and mechanical separation of aggregate, and (2) hydrocarbon treatment and processing. The Company successfully completed all commissioning efforts of the first phase and now continues to commission the second phase. Once those efforts are completed, the Empower Calgary Facility will be turned over to operations, currently scheduled for mid-year 2025. Plant Expansions - significant steps continued towards expansion efforts of the Company's business model, including: Empower Hamilton Facility – the Company executed a letter of intent with YORK1 Environmental Waste Solutions Ltd. to supply up to 10,000 tonnes of waste roofing shingles with an understanding to increase supply volumes through time. Execution of supply agreements represents a critical step in establishing a working facility. This first supply agreement followed closely on the announcement in late 2024 of the Company signing a letter of intent with the Great Lakes Port Management Inc., a subsidiary of the Hamilton-Oshawa Port Authority, for a long-term lease for an industrial zoned property located in Hamilton, Ontario as the site for the Company's planned facility in southwestern Ontario ; US Expansion – the Company continues to expend time and energy in the selection of a suitable site for our inaugural reprocessing facility in the United States . As has been previously communicated by the Company, selection criteria have focused on areas that represent an operational fit with the Company's strategic financial partner, TAMKO Building Products Inc.; and Empower Delta Facility – during the quarter, the Company successfully secured a fifteen-year lease at its existing Delta, British Columbia location. This paves the way to retro-fit the existing pilot facility at this location to a full-scale commercial facility. The site currently holds all necessary regulatory approvals and permits for light industrial operations, offering a future expansion opportunity with reduced timelines and costs associated with permitting and site development. Liquidity – commensurate with execution of the business plan, the Company successfully received proceeds under previously negotiated funding agreements, consisting of: $3.9 million from Emissions Reduction Alberta, subsequent to the quarter-end, upon completion of Milestone 2, which includes among other items, all major processing units installed and electrified and substantial completion as defined in the Builder's Lien Act; $617 thousand final draw subsequent to the quarter-end under the Business Development Bank $8.75 million non-revolving senior secured project loan facility; and $248 thousand received during the quarter from the exercise of existing stock options and warrants. Year-to-date, the Company has received $392 thousand from the exercise of stock options and warrants. Outstanding common shares as of May 29, 2025 totaled 137,051,985. Financial Results (CAD$, except per share amounts and common shares outstanding) Three Months Ended Mar. 31 FINANCIAL RESULTS 2025 2024 Loss and comprehensive loss 2,949,917 1,581,578 Per share - basic and diluted 0.02 0.01 Net cash flow used in operating activities 2,338,652 1,201,168 Per share - basic and diluted 0.02 0.01 Capital expenditures Capital expenditures 4,080,489 1,848,278 Liquidity & Capitalization Working capital (deficit) surplus (426,551) 3,440,770 7.95% senior secured non-revolving loan (1) 8,132,302 - Convertible debentures - principal amount (2) 9,505,000 5,700,000 Royalty debenture (3) 14,773,500 - Common shares outstanding Weighted average - basic and diluted 132,942,452 126,710,381 Outstanding, end of period 134,306,216 126,710,381 (1) As at March 31, 2025, the Company had drawn $8,132,302 from the BDC Financing, with $617,698 remaining undrawn. See Note 7 in the Company's Condensed Interim Consolidated Financial Statements as at March 31, 2025. (2) Since December 2022, the Company has entered into various financing arrangements through the issuance of convertible debentures in tranches, raising a total of $10,405,000 at interest rates varying between 10% and 12.5%. As at March 31, 2025, principal amounts totalling $9,505,000 remain outstanding, reflecting $900,000 of proceeds received in exchange for conversion into common shares. See Note 8 in the Company's Condensed Interim Consolidated Financial Statements as at March 31, 2025. (3) On September 13, 2024 the Company completed an agreement with CVW CleanTech Inc. ("CVW") pursuant to which CVW provided the Company with $14,000,000 in funding through a five-year 10.0% second secured convertible debenture (the "Royalty Debenture") convertible into revenue royalties on two future facilities. Balance includes the increase in fair value since inception. See Note 9 in the Company's Condensed Interim Consolidated Financial Statements as at March 31, 2025. About Northstar Northstar is a Canadian waste to value technology company focused on the sustainable recovery and reprocessing of asphalt shingles. Northstar developed and owns a proprietary design process for taking discarded asphalt shingles, otherwise destined for already over-crowded landfills, and extracts the liquid asphalt for use in new hot mix asphalt shingle manufacturing and asphalt flat roof systems while also extracting aggregate and fiber for use in construction products and other industrial applications. Focused on the circular economy, Northstar plans to reprocess used or defective asphalt shingle waste back into its three primary components for reuse/resale with its first commercial scale up facility in Calgary, Alberta . As an emerging innovator in sustainable processing, Northstar's mission aims at leading the recovery and reprocessing of asphalt shingles in North America that would otherwise be sent to landfill addressing numerous stakeholder objectives. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on For further information about Northstar, please visit On Behalf of the Board of Directors, President & CEO, Director Cautionary Statement on Forward-Looking Information Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. This press release may contain forward–looking information within the meaning of applicable securities legislation, which forward–looking information reflects the Company's current expectations regarding future events. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect", "aim", "objective" or similar expressions. Forward-looking statements in this press release include statements concerning: (i) Northstar's plans to reprocess used shingles into their component parts in the inaugural commercial facility in Calgary ; (ii) operations to commence mid-year 2025; (iii) the ability of the Company to expand into other regions, namely Hamilton, Ontario and the United States ; and (iv) Northstar's ability to become a leader in the recovery and reprocessing of asphalt shingles in North America . Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including: risks related to factors beyond the control of the Company; inability of the Company to execute on its business plans; the Company may require additional financing which may not be obtainable or on favourable terms; economic uncertainty; and the risks and uncertainties which are more fully described under the heading "Risk Factors" in the Company's annual and quarterly management's discussion and analysis and other filings with the Canadian securities regulatory authorities under the Company's profile on SEDAR+. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. The Company does not undertake any obligation to update such forward–looking information whether because of new information, future events or otherwise, except as expressly required by applicable law. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, expected or aimed. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. The Company does not intend, and does not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.
Globe and Mail
29 minutes ago
- Globe and Mail
The rising tide of childhood obesity
Thomas Verny is a clinical psychiatrist, academic, award-winning author, public speaker, poet and podcaster. He is the author of eight books, including the global bestseller The Secret Life of the Unborn Child and 2021's The Embodied Mind: Understanding the Mysteries of Cellular Memory, Consciousness and Our Bodies. In Canada 25 per cent of four- to 11-year-olds and 33 per cent of 12- to 17-year-olds are overweight or obese. [1] In the U.S. 14.4 million children and adolescents are affected by obesity. [2] International reports suggest that the global prevalence of pediatric obesity has tripled over the past 30 years, [3] a trend that likely accelerated during the COVID pandemic. [4] Celebrities including Oprah Winfrey, Kathy Bates, Elon Musk, Rosie O'Donnell, and many others have been quoted in the media as having lost considerable weight by taking drugs like Ozempic and Wegovy (both semaglutides) and Mounjaro and Zepbound (dual agonists tirzepatide). In the wake of this publicity, a growing number of obese adults and children have been prescribed Ozempic or similar medications. These drugs fall into the class of compounds known as GLP1 (glucagon-like peptide 1) agonists and the GLP-1/GIP dual agonists. They assist with weight loss by mimicking a natural hormone, GLP-1, that regulates appetite and digestion. It slows down food movement in the stomach, produces a feeling of fullness for longer, and sends signals to the brain to reduce hunger. Over time, this leads to reduced caloric intake and, consequently, weight loss. In response to the growing concern among health providers of the alarming rise of obesity among children and adolescents, the Canadian Medical Association Journal recently published 'Managing obesity in children: a clinical practice guideline.' [5] The paper is 54 pages long, compiled by 54 authors who make 10 recommendations and nine good practice statements for managing obesity in children. Wider benefits of Ozempic, Wegovy put pressure on Canadian insurers to expand drug coverage The Canadian study included youth, caregivers and multidisciplinary health care providers; it noted the magnitude of benefits and harms of each intervention, so that caregivers and health care providers can make informed decisions. The guideline rightly emphasizes that managing pediatric obesity requires support for both children and their families. The authors offer 'practical strategies to implement and sustain healthy behavioural changes, along with medication or surgical treatments when appropriate and accessible.' Here, I begin to question the wisdom of the guideline. I wonder how their 'practical strategies' work for doctors practising in the community rather than inhabiting the ivory tower of academia. For example, regarding the use of drugs, the guideline states: 'We suggest that glucagon-like peptide-1 receptor agonists be considered, in combination with behavioural and psychological interventions, for managing obesity in children aged 12 years and older [conditional recommendation, very low to low certainty of evidence].' OK. So, when your child's pediatrician or family doctor reads this 'suggestion,' it tells them that Ozempic or a similar drug should be considered. Well, any physician who has not been living in a cave somewhere in the Himalayas has read in their medical journals and/or attended conferences discussing glucagon-like peptide-1 receptor agonists. This is not news to them. To make matters worse, the guideline indicates that evidence for this recommendation is low to very low. If you were a doctor, would you ever prescribe a drug to a patient (unless it was an anti-cancer drug of last resort) that had a low or very low probability of success? How is this helpful to a pediatrician or a lay person? When diet, exercise and weight loss meds have proven unsuccessful, and a child faces significant health issues owing to excess weight, the guideline says, 'We recommend neither for nor against using technology interventions [why call metabolic or bariatric surgery technology except to avoid the term surgery?] for managing obesity in children aged 18 years and younger [conditional recommendation, very low to low certainty of evidence].' How practical is that? Can you call a recommendation, that is not a recommendation, a recommendation? Ask a doctor: Why won't my doctor prescribe Ozempic for weight loss? Perhaps the fact that of the 54 authors of the guideline only 15 were MDs and only two (yes, two) were practising pediatricians, might explain the theoretical vs the practical position this guideline has taken. The project was co-led by Dr. Geoff Ball, a professor of pediatrics and Alberta Health Services Chair in Obesity Research. That position came with funding used for the guideline. The rest came from Obesity Canada, which receives funding from what they euphemistically refer to as their Focus Partners, that on closer inspection turn out to be - surprise - big pharmaceuticals Novo Nordisk, maker of Ozempic and Wegovy, Lilly, maker of Mounjaro and Zepbound, plus Desjardins and Boehringer Ingelheim. When I wrote to Lisa Schaffer, the executive director of Obesity Canada, inquiring just how much money these pharma companies donated, I received no answer. Scientists are still puzzled by how the GLP-1 drugs affect the brain's eating control systems. This is not slam dunk. The way the body controls food intake is incredibly complicated. Prof. Harvey J. Grill of the University of Pennsylvania has studied the neurobiology of energy balance for years. Unique to his team's approach is the perspective that the neural control of food intake is anatomically distributed rather than centred in any one region of the brain. [6] Their perspective is also shaped by the notion that environmental factors influence feeding behaviour by creating associations between environmental cues and reward experiences, and that food palatability is flexible and can be altered by these reward experiences. Clearly, obesity can lead to a host of medical problems, including diabetes, liver disease, heart disease, cancers, sleep apnea and increased mortality. This is a serious condition. Therefore, prevention and treatment, especially early on, is paramount. The new weight loss drugs can be miraculous in the short term but are not a panacea. And, as indicated above, we do not really know all the effects they may have on our brains. It seems to me that you can gain and retain weight in two ways. You put more calories into a normally functioning body than you put out. That's psychological. It often has the hallmarks of an addiction. Or, you have a normal caloric intake, but you retain more than you put out. That's physical. In other words, your body does not metabolize the food you ingest properly. I am referring to conditions such as hypothyroidism, Cushing's Disease, diabetes, insomnia, sleep apnea, and taking common medications such as antipsychotics, antidepressants, epilepsy drugs, and beta-blockers (for high blood pressure) which can lead to weight gain and, will of course, be managed accordingly. Cheaper, generic versions of Ozempic could come to Canada as early as next year If you are going to treat a child for obesity, or an adult for that matter, it is essential to know whether the weight gain is psychological or biological in origin. Often one leads to the other when both need to be addressed. Although it is an accepted fact that the primary prevention of obesity in children is an essential public health issue, [7] this guideline does not address it. It should be noted that a recent Brazilian study of 728 infants found that more than 80 per cent of them consumed ultra-processed foods before age two, despite global health recommendations. Ultra-processed foods can harm gut microbiota diversity linked to gastrointestinal issues and obesity. The researchers found that breastfeeding attenuated the harmful effects of consuming ultra-processed foods on the composition of the gut microbiota. And children who received breast milk and did not consume ultra-processed products did even better in the long run. [8] It is time that health care providers started to pay attention to early factors associated with obesity rather than essentially closing the metaphorical barn door after the horses have trotted off. Many studies show that a considerable number of children and adolescents who are obese use food as a maladaptive coping mechanism in response to experiences of childhood trauma. [9] Therefore, whenever possible, physicians should speak with the child or adolescent on their own a few times and inquire carefully about a history of physical, sexual or emotional abuse, neglect, parental arguing or violence, separation or untimely death of a parent. Bullying may be another issue that a child may hesitate to talk about in the presence of a parent. [10] Depression or treatment for depression with antidepressant drugs may be a contributing factor in weight gain. [11] Obviously, all the above produce additional stress on both child and parent, which exacerbates the problem. We don't know how much genetics contributes to obesity. What we do know is that if either parent or both parents are obese a discussion with them about their lifestyle is indicated. Do they dine as a family and talk to each other or eat separately while watching TV? What kinds of food do they eat? How often do they eat out and if so, where? Parents are role models for their children. If you are a parent keep in mind that you need to practice what you preach. Unfortunately, caloric restriction (dieting) as the sole treatment for obesity has proven ineffective as any achieved weight loss alters physiology in a way that facilitates weight regain. The same can be said about weight loss drugs and bariatric surgery. All the pediatricians I spoke to agreed that sustainable weight loss involves a balanced approach, including increasing healthful food consumption, participation in physical activity for enjoyment and self-care reasons, improvement in self-esteem and self-concept, stress management, and adequate sleep. They hardly ever prescribe Ozempic and similar drugs because of rare but serious side effects, a lack of long-term studies in children and because most children don't like the prospect of weekly needles. According to the CMAJ paper, 'Obesity is a complex, chronic, progressive, and highly stigmatized disease that increases risk for more than 200 health conditions.' This is a mantra that gets repeated over and over again, by many health providers and organizations. I do not think obesity is a disease. It can certainly lead to ill health but so can many other habits or activities such as smoking, driving a car or skiing. Obesity, as I see it, is neither a moral failing nor a disease but rather a multi-factorial psychosomatic condition that must be approached with empathy and support free of preconceived notions, keeping in mind that more attention to early prevention would decrease the need for treatment later. 1. Hampl, S. E., Hassink, S. G., Barlow. S. E., Bolling, C. F., … & Okechukwu, K. (2023). Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics, 151(2). 2. Press Release, Obesity Canada, 2025 3. Kerr, J. A., Patton, G. C., Magied, A. H., … & Azzolino, D. (2025). Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet, 405(10481), 785-812 4. Dietz, W. H. (2023). The COVID‐19 lockdown increased obesity disparities; will the increases in type 2 diabetes continue?. Obesity, 31(3), 699-702. 5. Ball, G. D., Merdad, R., Hadjiyannakis, S., … & Johnston, B. C. (2025). Managing obesity in children: a clinical practice guideline. CMAJ, 197(14), E372-E38933 6. Grill, Harvey. 7. Lister, N. B., Baur, L. A., Reinehr, T., … & Wabitsch, M. (2023). Child and adolescent obesity. Nature Reviews Disease Primers, 9(1), 24. 8. Faggiani, L. D., de França, P., Qi, L., & Cardoso, M. A. (2025). Effect of ultra-processed food consumption on the gut microbiota in the first year of life: findings from the MINA-Brazil birth cohort study. Clinical Nutrition. 9. Offer, S., Alexander, E., Flint, S. W., & Lawrence, B. J. (2022). The association between childhood trauma and overweight and obesity in young adults: the mediating role of food addiction. Eating and Weight Disorders-Studies on Anorexia, Bulimia and Obesity, 27(8), 3257-3266. 10. Hadjiyannakis, S., Ibrahim, Q., Hamilton, J. K., … & Morrison, K. M. (2019). Obesity class versus the Edmonton Obesity Staging System for Pediatrics to define health risk in childhood obesity: results from the CANPWR cross-sectional study. The Lancet Child & Adolescent Health, 3(6), 398-407. 11. Petimar, J., Young, J. G., M. F., Heerman, W. J., … & Block, J. P. (2024). Medication-induced weight change across common antidepressant treatments: a target trial emulation study. Annals of internal medicine, 177(8), 993-1003.
Cision Canada
31 minutes ago
- Cision Canada
BMO Recognized for Digital Innovation and Customer Experience Français
TORONTO, May 30, 2025 /CNW/ - BMO today announced it has received multiple recognitions for its leadership in delivering innovative digital solutions and experiences to help customers make real financial progress. Digital CX Awards from The Digital Banker: Outstanding Digital CX for Mobile Banking – Canada: Available in BMO's Mobile Banking app and Online Banking, the Enhanced Transaction Details feature provides customers with detailed information about credit and debit card transactions including merchant information and location. This provides customers a more comprehensive understanding of their transactions and spending habits. Excellence in Omni-Channel Customer Experience: BMO developed an approach to helping customers make progress towards the financial goals by delivering personalized and relevant multi-channel advice and guidance to support their journey. Customers are able to share their financial goals in-branch, over email, or on BMO Savings Goals, a feature available on the BMO Mobile Banking app and Online Banking. Editor's Choice Award from Banking Tech Awards: BMO was also recognized for its success in creating and integrating seamless digital experiences to meet customers where they are in their financial journey across four initiatives: InnoV8 Customer Feedback Assist: The large language model (LLM) powered tool is designed to help BMO address feedback received from customer reviews. Taking elements of a traditional dashboard and adding LLM powered data, this cohesive solution improves employees' workflow and helps support the continuous improvement efforts for customers. BMO SmartProgress: BMO SmartProgress is a free, online financial education platform accessible to all Canadians to help them learn about personal finance topics and make real financial progress. With over 40 interactive, customized modules on financial planning topics, including budgeting and credit management, homeownership and investing, Canadians can conveniently build their financial literacy anywhere and at any time. Digital Card Controls: A quick solution for customers facing time sensitive issues, BMO's Digital Card Controls feature suite helps customers when dealing with a lost wallet, damaged cards, or forgotten PINs. With this convenient solution, customers are empowered to manage their cards anywhere and at any time. BMO's Bank of the West Integration: Following BMO's 2021 acquisition of Bank of the West, BMO successfully integrated its systems in 2023, maintaining existing login credentials, converting digital profiles and guiding customers through an individualized onboarding journey. BMO's innovative approach included converting all money movement transactions, providing customized guidance and enhancing foundational technology for scale. The project successfully converted 1.8 million customers and over 500 branches. "At BMO, our commitment to elevating our customers' everyday banking experiences drives our digital and innovation agenda," said Mat Mehrotra, Chief Digital Officer and Head of Canadian Products, BMO. "These recognitions reinforce how we are empowering our customers by meeting them where they are with differentiated experiences that help them make real financial progress." The Digital CX Awards is the world's only program dedicated to recognizing pioneering innovation in the Digital Customer Experience across the Financial Services ecosystem. The awards honour excellence in the use of digital assets within the financial services industry and celebrates contributions to innovations, technological enhancements and commitments to digital transformation. The Editor's Choice Award is chosen by the editorial team of FinTech Futures, a globally trusted resource recognizing banking and fintech innovation. The award recognizes a financial services organization that has successfully delivered innovative and impactful technology projects, with tangible results and perceptible, positive impact. BMO continues to pave the way as a digitally enabled, future-ready bank, focused on delivering leading digital experiences that help customers make real financial progress. These recognitions demonstrate BMO's Digital First journey and build on the bank's strong track record of industry credits. For more information about the Digital CX Awards, please visit: BMO Financial Group is the seventh largest bank in North America by assets, with total assets of $1.4 trillion as of April 30, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.
